The FDA has approved Merck’s Zolinza capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. Zolinza is manufactured by Patheon, Inc. in Mississauga, ON. Zolinza was approved as part of FDA’s Orphan Drug program, which offers companies incentives to develop medications for diseases affecting fewer than 200,000 Americans a year. E...